CADTH Canadian Drug Expert Committee recommendation: Guselkumab (Tremfya -- Janssen Inc.) indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics fo...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
February 21, 2018, 2018
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that guselkumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, with the following criteria and condition. Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response to treatment with guselkumab has not been demonstrated after 16 weeks |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (9 pages) |